Anika Therapeutics (ANIK)
NASDAQ:ANIK
Want to see ANIK full AI Analyst Report?
ANIK Stock Chart & Stats
$9.75
$0.27(1.72%)
At close: 4:00 PM EST
$9.75
$0.27(1.72%)
Day’s Range― - ―
52-Week Range$7.87 - $16.24
Previous CloseN/A
Volume22.29K
Average Volume (3M)174.95K
Market Cap
$195.86M
Enterprise Value$178.05M
Total Cash (Recent Filing)$41.02M
Total Debt (Recent Filing)$25.74M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 05, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding13,305,624
10 Day Avg. Volume181,118
30 Day Avg. Volume174,954
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.96
Price to Sales (P/S)1.22
P/FCF Ratio31.59
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda-38.42
Forecast
1Y Price Target
$17.00Price Target Upside74.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$118.61M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial TractionDouble-digit revenue growth across Commercial and OEM channels plus strong procedure adoption (Integrity U.S. procedures +35%) signal durable product-market fit and expanding clinician adoption. Multi-channel growth reduces reliance on any single customer type and supports scalable recurring product sales over coming quarters.
Margin Expansion From Manufacturing ProductivitySizable gross-margin improvement reflects structural operational gains—higher throughput, equipment investment and lean manufacturing—which can sustainably lower unit costs. These efficiency gains underpin durable margin support and improved operating leverage as commercial volumes scale, strengthening long-term profitability potential.
Conservative Balance Sheet And LiquiditySolid cash reserves and low leverage provide lasting financial flexibility to fund regulatory programs, commercial expansion and capital investments without immediate financing pressure. This buffer reduces refinancing risk and supports strategic choices during multi-quarter regulatory or commercial execution timelines.
Bears Say
Recurring Losses And Negative MarginsPersistent operating and net losses erode equity and limit retained earnings, constraining the firm's ability to self-fund growth and return capital. Over time, continued negative margins can force cost cutting, dilution, or slower commercial investment, weakening competitive positioning relative to profitable peers.
Inconsistent Cash Generation And Sharp FCF DeclineHighly variable free cash flow and a steep year-over-year decline reduce the company's stable funding capacity for R&D, regulatory trials and commercial ramps. This volatility raises the likelihood of funding dependencies or constrained investment pacing, increasing execution risk across multi-quarter initiatives.
Regulatory Timing Risk And OEM Revenue VariabilityUncertain FDA timelines for Hyalofast and CINGAL can materially delay U.S. commercialization and expected revenue, while OEM ordering variability creates recurring quarter-to-quarter sales volatility. Together these structural execution risks impair revenue predictability and complicate long-term capacity and investment planning.
Anika Therapeutics News
ANIK FAQ
What was Anika Therapeutics’s price range in the past 12 months?
Anika Therapeutics lowest stock price was $7.87 and its highest was $16.24 in the past 12 months.
What is Anika Therapeutics’s market cap?
Anika Therapeutics’s market cap is $195.86M.
When is Anika Therapeutics’s upcoming earnings report date?
Anika Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 53 days.
How were Anika Therapeutics’s earnings last quarter?
Anika Therapeutics released its earnings results on Apr 29, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of -$0.07 by $0.34.
Is Anika Therapeutics overvalued?
According to Wall Street analysts Anika Therapeutics’s price is currently Undervalued.
Does Anika Therapeutics pay dividends?
Anika Therapeutics does not currently pay dividends.
What is Anika Therapeutics’s EPS estimate?
Anika Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Anika Therapeutics have?
Anika Therapeutics has 13,305,624 shares outstanding.
What happened to Anika Therapeutics’s price movement after its last earnings report?
Anika Therapeutics reported an EPS of $0.27 in its last earnings report, beating expectations of -$0.07. Following the earnings report the stock price went down -18.807%.
Which hedge fund is a major shareholder of Anika Therapeutics?
Currently, no hedge funds are holding shares in ANIK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anika Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.00 (74.36% Upside)
$17.00 (74.36% Upside)
Blogger Sentiment
Bullish
ANIK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $223.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.14%
12-Months-Change
Fundamentals
Return on Equity
-7.74%
Trailing 12-Months
Asset Growth
-5.89%
Trailing 12-Months
Company Description
Anika Therapeutics
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
ANIK Company Deck
ANIK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful commercial momentum (13% revenue growth), strong operational improvements (gross margin up ~8 percentage points and adjusted EBITDA lift), accelerating adoption of Integrity and international product strength, supported by a clean balance sheet and active share repurchase. Key near-term concerns include higher operating expenses (notably a onetime $4.9M severance), regulatory timelines for Hyalofast and CINGAL that remain uncertain, OEM channel timing and mix variability, and caution that Q1 margin levels may not be fully sustained quarter-to-quarter. Overall, the positives around revenue growth, margin improvement, pipeline progress and liquidity outweigh the manageable near-term risks and uncertainties.View all ANIK earnings summariesANIK Stock 12 Month Forecast
Average Price Target
$17.00
▲(74.36% Upside)
Technical Analysis
Ownership Overview
5.55% Insiders
12.34% Mutual Funds
20.41% Other Institutional Investors
49.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---